Endometrial and follicular development following stair-step and traditional protocols in women with polycystic ovary syndrome: An RCT.
Clomiphene
Infertility
Ovulation induction.
Polycystic ovary syndrome
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
06
04
2020
revised:
18
07
2020
accepted:
10
10
2020
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
Various strategies have been proposed for polycystic ovary syndrome (PCOS) treatment. To investigate and compare the number and size of ovarian follicles, endometrial thickness, and ovulation rate by traditional protocol (TP) and stair-step protocol (SSP). Sixty infertile PCOS women were allocated into two groups (SSP = 30 and control TP = 30) between May and October 2019 in the Besat Hospital, Sanandaj, Iran. In the SSP group, the infertile women were treated with 50 mg/daily clomiphene citrate (CC) for five days, while the nonresponsive women were prescribed 100 mg daily CC for five days in the same cycle. The maximum dose (150 mg) was administered until ovulation occurred. In the control group, in non-ovulatory cases, the dose was increased in the next cycle. Ultrasound was used to detect ovulation. Endometrial thickness changes with various doses of CC were significantly different in the TP. The comparison of both protocols showed a significant difference in endometrial thickness only at 50 mg CC. The number of follicles in the left ovary was significantly different in both protocols at 150-mg CC. The size of ovarian follicles in the left ovary was significantly different between the two protocols at 100-mg CC. The ovulation rate was significantly different in the SSP at 100- and 150-mg doses of CC. Moreover, 86% of ovulation occurred at 100-mg CC in the SSP, while this rate was 73% in the TP. The most appropriate dose for ovulation in patients with PCOS is 100 mg CC.
Sections du résumé
BACKGROUND
BACKGROUND
Various strategies have been proposed for polycystic ovary syndrome (PCOS) treatment.
OBJECTIVE
OBJECTIVE
To investigate and compare the number and size of ovarian follicles, endometrial thickness, and ovulation rate by traditional protocol (TP) and stair-step protocol (SSP).
MATERIALS AND METHODS
METHODS
Sixty infertile PCOS women were allocated into two groups (SSP = 30 and control TP = 30) between May and October 2019 in the Besat Hospital, Sanandaj, Iran. In the SSP group, the infertile women were treated with 50 mg/daily clomiphene citrate (CC) for five days, while the nonresponsive women were prescribed 100 mg daily CC for five days in the same cycle. The maximum dose (150 mg) was administered until ovulation occurred. In the control group, in non-ovulatory cases, the dose was increased in the next cycle. Ultrasound was used to detect ovulation.
RESULTS
RESULTS
Endometrial thickness changes with various doses of CC were significantly different in the TP. The comparison of both protocols showed a significant difference in endometrial thickness only at 50 mg CC. The number of follicles in the left ovary was significantly different in both protocols at 150-mg CC. The size of ovarian follicles in the left ovary was significantly different between the two protocols at 100-mg CC. The ovulation rate was significantly different in the SSP at 100- and 150-mg doses of CC. Moreover, 86% of ovulation occurred at 100-mg CC in the SSP, while this rate was 73% in the TP.
CONCLUSION
CONCLUSIONS
The most appropriate dose for ovulation in patients with PCOS is 100 mg CC.
Identifiants
pubmed: 34401648
doi: 10.18502/ijrm.v19i6.9375
pmc: PMC8350856
doi:
Types de publication
Journal Article
Langues
eng
Pagination
537-544Informations de copyright
Copyright © 2021 Shahgheibi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):15-29
pubmed: 28724177
J Nippon Med Sch. 2002 Aug;69(4):328-32
pubmed: 12187364
BJOG. 2018 Feb;125(3):299-308
pubmed: 28544572
Ther Adv Reprod Health. 2020 May 22;14:2633494120908818
pubmed: 32518914
Endokrynol Pol. 2013;64(5):409-14
pubmed: 24186599
Reprod Med Biol. 2004 Aug 10;3(3):153-157
pubmed: 29699195
J Hum Reprod Sci. 2017 Oct-Dec;10(4):261-264
pubmed: 29430152
Int J Gynaecol Obstet. 2003 Jun;81(3):287-92
pubmed: 12767571
J Perinatol. 2012 Oct;32(10):770-6
pubmed: 22261835
Hum Reprod. 2005 Aug;20(8):2043-51
pubmed: 15878925
Hum Reprod. 2011 Jul;26(7):1768-74
pubmed: 21558332
J Ovarian Res. 2016 Feb 11;9:3
pubmed: 26864649
Am J Obstet Gynecol. 2009 May;200(5):510.e1-4
pubmed: 19114272
Obstet Gynecol. 2018 Jan;131(1):91-95
pubmed: 29215516
Arch Gynecol Obstet. 2015 Jan;291(1):179-84
pubmed: 25078053
Gynecol Endocrinol. 2012 Feb;28(2):87-90
pubmed: 21770837
Fertil Steril. 2019 Mar;111(3):571-578.e1
pubmed: 30683591
J Steroid Biochem Mol Biol. 2018 Sep;182:27-36
pubmed: 29678491